Alternative Agents Versus Prophylactic Platelet Transfusion for Preventing Bleeding in Patients with Haematological Disorders After Chemotherapy or Stem Cell Transplantation

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2015 Feb 28

PMID 25722650

Citations 5

Authors

Lise J Estcourt

Richard Gregg

Simon Stanworth

Carolyn Doree

Marialena Trivella

Michael F Murphy

Alan Tinmouth

Affiliations

Soon will be listed here.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine whether alternative agents (e.g. artificial platelet substitutes, platelet-poor plasma, fibrinogen, rFVIIa, thrombopoietin mimetics) are as effective and safe as the use of platelet transfusions for the prevention of bleeding (prophylactic platelet transfusion) in patients with haematological disorders who are undergoing myelosuppressive chemotherapy or stem cell transplantation. Antifibrinolytics (lysine analogues) will not be included in this review because they have been the focus of another Cochrane review (Wardrop 2013).

Citing Articles

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.

Desborough M, Estcourt L, Doree C, Trivella M, Hopewell S, Stanworth S Cochrane Database Syst Rev. 2016; (8):CD010982.

PMID: 27548292 PMC: 5019360. DOI: 10.1002/14651858.CD010982.pub2.

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.

Desborough M, Estcourt L, Chaimani A, Doree C, Hopewell S, Trivella M Cochrane Database Syst Rev. 2016; 2016(1).

PMID: 27069420 PMC: 4826602. DOI: 10.1002/14651858.CD012055.

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Estcourt L, Stanworth S, Doree C, Hopewell S, Trivella M, Murphy M Cochrane Database Syst Rev. 2015; (11):CD010983.

PMID: 26576687 PMC: 4717525. DOI: 10.1002/14651858.CD010983.pub2.

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Estcourt L, Stanworth S, Doree C, Trivella M, Hopewell S, Blanco P Cochrane Database Syst Rev. 2015; (10):CD010984.

PMID: 26505729 PMC: 4724938. DOI: 10.1002/14651858.CD010984.pub2.

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Crighton G, Estcourt L, Wood E, Trivella M, Doree C, Stanworth S Cochrane Database Syst Rev. 2015; (9):CD010981.

PMID: 26422767 PMC: 4610062. DOI: 10.1002/14651858.CD010981.pub2.

References

Gratwohl A, Baldomero H, Aljurf M, Pasquini M, Bouzas L, Yoshimi A . Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303(16):1617-24. PMC: 3219875. DOI: 10.1001/jama.2010.491. View

Estcourt L, Stanworth S, Murphy M . Platelet transfusions for patients with haematological malignancies: who needs them?. Br J Haematol. 2011; 154(4):425-40. DOI: 10.1111/j.1365-2141.2010.08483.x. View

Miao M, Wu D, Cao X, Dong W, Wang B, Ou Y . [Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2012; 33(5):362-5. View

Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C . Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012; (3):CD005011. DOI: 10.1002/14651858.CD005011.pub4. View

Coleman M, Rachet B, Woods L, Mitry E, Riga M, Cooper N . Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer. 2004; 90(7):1367-73. PMC: 2409687. DOI: 10.1038/sj.bjc.6601696. View

Higby D, Cohen E, HOLLAND J, Sinks L . The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion. 1974; 14(5):440-6. DOI: 10.1111/j.1537-2995.1974.tb04558.x. View

Sorensen B, Tang M, Larsen O, Laursen P, Fenger-Eriksen C, Rea C . The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding. Thromb Res. 2012; 128 Suppl 1:S13-6. DOI: 10.1016/S0049-3848(12)70004-X. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Slichter S . Controversies in platelet transfusion therapy. Annu Rev Med. 1980; 31:509-40. DOI: 10.1146/annurev.me.31.020180.002453. View

10.

Okamura Y, Fukui Y, Kabata K, Suzuki H, Handa M, Ikeda Y . Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation. Bioconjug Chem. 2009; 20(10):1958-65. DOI: 10.1021/bc900325w. View

11.

Heddle N, Arnold D, Boye D, Webert K, Resz I, Dumont L . Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion. 2008; 48(7):1447-58. DOI: 10.1111/j.1537-2995.2008.01731.x. View

12.

Slichter S . Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program. 2007; :172-8. DOI: 10.1182/asheducation-2007.1.172. View

13.

Benson A, Moss M, Silliman C . Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol. 2009; 147(4):431-43. PMC: 4532338. DOI: 10.1111/j.1365-2141.2009.07840.x. View

14.

Okamura Y, Takeoka S, Eto K, Maekawa I, Fujie T, Maruyama H . Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost. 2009; 7(3):470-7. DOI: 10.1111/j.1538-7836.2008.03269.x. View

15.

Solomon J, Bofenkamp T, Fahey J, Chillar R, Beutel E . Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet. 1978; 1(8058):267. DOI: 10.1016/s0140-6736(78)90505-6. View

16.

Estcourt L, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy M . Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sang. 2012; 103(4):284-93. DOI: 10.1111/j.1423-0410.2012.01627.x. View

17.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

18.

. Guidelines for the use of platelet transfusions. Br J Haematol. 2003; 122(1):10-23. DOI: 10.1046/j.1365-2141.2003.04468.x. View

19.

Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymondos K, Scheinichen D . Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth. 2010; 104(5):555-62. PMC: 2855672. DOI: 10.1093/bja/aeq058. View

20.

Greeno E, McCullough J, Weisdorf D . Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion. 2007; 47(2):201-5. DOI: 10.1111/j.1537-2995.2007.01089.x. View